<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652284</url>
  </required_header>
  <id_info>
    <org_study_id>900-20-RMC</org_study_id>
    <nct_id>NCT04652284</nct_id>
  </id_info>
  <brief_title>Effectiveness of Rifabutin for Treatment of Helicobacter Pylori</brief_title>
  <official_title>Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effectiveness of rifabutin triple therapy for the&#xD;
      treatment of H. pylori infection in the Israeli population. Patients with or without a prior&#xD;
      history of H. pylori eradication failure will be randomized to receive one of three possible&#xD;
      treatments:&#xD;
&#xD;
      Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2-&#xD;
      amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of&#xD;
      care&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who present to the outpatient gastroenterology clinic at our institution with a&#xD;
      positive diagnostic test for H pylori will be screened. Included patients will undergo&#xD;
      randomisation into 3 groups. Randomization will be performed by a random sequence generator&#xD;
      to create equal sized groups in boxes of 12.&#xD;
&#xD;
      Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2-&#xD;
      amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of&#xD;
      care Standard of care in previously untreated patients will consist of concomitant treatment&#xD;
      (amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole all given&#xD;
      twice daily for 14 days). In previously treated patients standard of care will consist of&#xD;
      bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment&#xD;
      where available.&#xD;
&#xD;
      Treatment duration will be 14 days in all groups. Patients who are randomised to Group 3 and&#xD;
      fail treatment will be offered open label rescue treatment with amoxicillin 1000mg bd,&#xD;
      rifabutin 150 mg bd and esomeprazole 40 mg bd (14 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, non-blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of H. pylori treatment</measure>
    <time_frame>6 weeks following end of treatment</time_frame>
    <description>Negative 13C-urea breath test or Helicobacter pylori Stool Ag</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>14 days treatment</time_frame>
    <description>Daily entry of Likert scale (0-10) for the following parameters: diarrhea, nausea, abdominal pain, dyspepsia, reflux, loss of appetite, asthenia and others (free text). Adverse effects leading to treatment discontinuation. Serious adverse events leading to leading to patient's hospitalization, disability, or death, or to birth defects on pregnant patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with H. pylori treatment</measure>
    <time_frame>14 days treatment</time_frame>
    <description>Assessed by diary entry twice daily. If more than 80% of pills taken, patient considered to be treatment compliant.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Helicobacter Infections</condition>
  <condition>Resistance Bacterial</condition>
  <condition>Gastritis H Pylori</condition>
  <arm_group>
    <arm_group_label>Rifabutin full dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifabutin low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care in previously untreated patients will consist of concomitant treatment (oral amoxicillin 1000mg, clarithromycin 500 mg, tinidazole 500 mg and esomeprazole 40 mg all given twice daily for 14 days). In previously treated patients standard of care will consist of bismuth quadruple therapy, quinolone based therapy, or other susceptibility guided treatment where available</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>150 mg</description>
    <arm_group_label>Rifabutin full dose</arm_group_label>
    <arm_group_label>Rifabutin low dose</arm_group_label>
    <other_name>mycobutin速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>1000 mg</description>
    <arm_group_label>Rifabutin full dose</arm_group_label>
    <arm_group_label>Rifabutin low dose</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Amoxil速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40 mg</description>
    <arm_group_label>Rifabutin full dose</arm_group_label>
    <arm_group_label>Rifabutin low dose</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>&quot;nexium&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>500 mg</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Biaxin速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinidazole</intervention_name>
    <description>500 mg</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>protocide速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting to outpatient clinic with evidence of H. pylori infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to any of the study drugs&#xD;
&#xD;
          -  prior exposure to rifamycin drugs&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  haematological disease&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  active malignancy&#xD;
&#xD;
          -  immune suppression&#xD;
&#xD;
          -  patients not expected to benefit from Helicobacter pylori eradication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doron Boltin, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doron Boltin, MBBS</last_name>
    <phone>972504488881</phone>
    <email>dboltin@gmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021 Jun;36(6):1392-1402. doi: 10.1111/jgh.15294. Epub 2020 Oct 29.</citation>
    <PMID>33037845</PMID>
  </results_reference>
  <results_reference>
    <citation>Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734. Epub 2020 May 5.</citation>
    <PMID>32365359</PMID>
  </results_reference>
  <results_reference>
    <citation>Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006 Feb 15;23(4):481-8. Erratum in: Aliment Pharmacol Ther. 2006 Jul 15;24(2):439.</citation>
    <PMID>16441468</PMID>
  </results_reference>
  <results_reference>
    <citation>Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two &quot;rescue&quot; therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001 Jan;96(1):58-62.</citation>
    <PMID>11197288</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>anonymized IPD will be available upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>will be available following publication of results for a period of 7 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

